Biomet Biologics, LLC

Biomet Manufacturing Corporation

Other

Biomet, Inc.

Biomet Biologies, LLC

Joel C Higgins

Jennifer E Woodell-May

Michael D Leach

Jacy C Hoeppner

Brandon Miller

Matthew Swift

Krista O'Shaughnessey

Nathan Gordon

William King

Matthew D Landrigan

Garry Lee England

Bruce Jay Simon

Krista O'shaughnessey

Jason M Chavarria

Ned M Hamman

Barry F Hecker

Alan David Gray

Grant Cunningham

Hillary Overholser

David R Brown

Brian David Salyer

James M McKale

James M Mckale

Gregory David VanDeWater

Jeffrey R Binder

Jacy Hoeppner

Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages. A blood fraction including platelet-poor plasma polarizes the source of macrophages into M1 macrophages. A blood faction including a protein solution polarizes the source of macrophages into M2 macrophages.

Methods of mediating macrophage phenotypes

Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

Methods and compositions for delivering interleukin-1 receptor antagonist

Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in IL-1ra can also include at least one of sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-&#x3b2;1, and sIL-1 RII.

Methods for making cytokine compositions from tissues using non-centrifugal methods

An apparatus may allow separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample and mesenchymal stem cells from bone reaming material. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Apparatus and method for separating and concentrating fluids containing multiple components

Methods for treating pain using a protein solution comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-&#x3b2;1, and sIL-1RII, Compositions may also contain white blood cells and platelets.

Treatment of pain using protein solutions

Methods for making non-immunogenic anti-inflammatory cytokine compositions, comprising (a) obtaining a liquid comprising cytokine producing cells from a mammalian donor; (b) contacting the liquid with a solid extraction material to generate a composition rich in interleukin-1 receptor antagonist; and performing one or both of (i) removing cells from the composition and (ii) freezing the composition. The compositions comprise two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-&#x3b2;1, and sIL-1RII, Compositions may also contain white blood cells and platelets.

Methods and non-immunogenic compositions for treating inflammatory disorders

A material separation system and method is disclosed. The system may include a buoy having a volume that includes or houses a reacting component. The buoy may be placed in a container to hold the material to be separated during a separation procedure. The separated material may be used to various procedures following separation.

System and method for separating a fraction

A clotting serum production device including a main chamber, an inlet housing, and an outlet port. The main chamber is defined by a first end wall, a second end wall opposite to the first end wall, and a side wall extending between the first end wall and the second end wall. The inlet housing extends from the first end wall. The inlet housing includes a first inlet port, a second inlet port, and a first conduit extending between the first inlet port and a second conduit. The second conduit extends between the second inlet port and the main chamber. The inlet housing is configured to provide one-way fluid flow from the first inlet port to the second inlet port and to provide one-way fluid flow from the second inlet port to the main chamber. An outlet port is in fluid communication with the main chamber and provides fluid communication with an exterior of the clotting serum production device.

Method and apparatus to create autologous clotting serum

Methods for transfusing blood to a mammalian subject. The method includes obtaining a unit of blood, rejuvenating the blood with an enhancement composition, measuring a level of 2,3-diphosphoglycerate in the blood, and delivering the blood to a subject.

Methods for rejuvenating red blood cells

Treatments and devices for generating and using interleukin-1 receptor antagonist (IL-1ra). An implantable device is loaded with adipose tissue and/or white blood cells and inserted into an inflammation site in a patient to produce interleukin-1 receptor antagonist in vivo. The implantable device has an enclosed or substantially enclosed body that defines an internal space. At least a portion of the body comprises a first bioresorbable material and a second bioresorbable material is within the internal space along with one or more voids. The second bioresorbable material includes an activation surface to activate adipose tissue and/or white blood cells loaded into the device to produce IL-1ra.

Implantable device for production of interleukin-1 receptor antagonist

Acellular compositions for treating inflammation, comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-&#x3b2;1, and sIL-1RII. Components of the acellular compositions may be derived from biologic materials, such as blood clots and urine. Components may also be obtained from cell cultures.

Growing community of inventors

Claypool, IN, United States of America

Joel C Higgins